John P. Hamill - 12 Mar 2026 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Reporting relationship: SrVP/CFO/Prin Fin & Acct Ofcr
Issuer ticker: APRE
Reported as of: 12 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Mar 2026, 18:06:04 UTC
Prior SEC filing: 02 Feb 2026
Next SEC filing: 01 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ John Hamill

Key filing fact

John P. Hamill filed Form 4 for Aprea Therapeutics, Inc. (APRE) on 16 Mar 2026.

Key facts

This page summarizes John P. Hamill's Form 4 filing for Aprea Therapeutics, Inc. (APRE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 16 Mar 2026, 18:06.

Change

Previous filing in this sequence was filed on 02 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001716213 Primary reporting owner

Hamill John P.

Relationship: SrVP/CFO/Prin Fin & Acct Ofcr
Address: 3805 OLD EASTON ROAD, DOYLESTOWN
Signature: /s/ John Hamill
Signature date: 16 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APRE transaction

Common Stock

Award

Transaction value
Shares: +10,095
Change %: +30%
Price: $0.000000^*
Shares after: 43,528
Date: 12 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APRE transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value
Shares: +40,380
Change %
Price: $0.000000^*
Shares after: 40,380
Date: 12 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,380
Exercise price: $0.7650
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 12, 2027, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.

Footnote F2

Twenty-five percent of these options vest on March 12, 2027, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.